476 related articles for article (PubMed ID: 20583852)
1. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
[TBL] [Abstract][Full Text] [Related]
2. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
3. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
[TBL] [Abstract][Full Text] [Related]
4. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
Hartz I; Sakshaug S; Furu K; Engeland A; Eggen AE; Njølstad I; Skurtveit S
BMC Clin Pharmacol; 2007 Dec; 7():14. PubMed ID: 18053228
[TBL] [Abstract][Full Text] [Related]
5. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Curr Med Res Opin; 2008 Jul; 24(7):1987-2000. PubMed ID: 18554430
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.
Bożentowicz-Wikarek M; Kocełak P; Smertka M; Olszanecka-Glinianowicz M; Chudek J
Pharmacol Rep; 2012; 64(2):377-85. PubMed ID: 22661189
[TBL] [Abstract][Full Text] [Related]
7. A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data.
Ofori-Asenso R; Ilomäki J; Zomer E; Curtis AJ; Zoungas S; Liew D
Cardiovasc Drugs Ther; 2018 Jun; 32(3):265-272. PubMed ID: 29790056
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
9. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002.
Teeling M; Bennett K; Feely J
Br J Clin Pharmacol; 2005 Feb; 59(2):227-32. PubMed ID: 15676046
[TBL] [Abstract][Full Text] [Related]
10. Differences between statins on clinical endpoints: a population-based cohort study.
Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
[TBL] [Abstract][Full Text] [Related]
12. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Bakhai A; Rigney U; Hollis S; Emmas C
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
[TBL] [Abstract][Full Text] [Related]
14. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.
Foody JM; Joyce AT; Jeffers BW; Liu LZ; Benner JS
Am J Ther; 2011; 18(2):110-6. PubMed ID: 20216383
[TBL] [Abstract][Full Text] [Related]
15. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
16. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
19. Impact of high dose statin trials on hospital prescribers.
Barron TI; Bennett K; Feely J
Eur J Clin Pharmacol; 2007 Jan; 63(1):65-72. PubMed ID: 17115149
[TBL] [Abstract][Full Text] [Related]
20. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Molden E; Skovlund E; Braathen P
Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
